	Le Bénéfice D'Exploitation		Date
AbbVie	USD 5.81B	1.23B	2025-12
Acadia Pharmaceuticals	USD 17.39M	18.36M	2025-12
ALKERMES	USD -10.95M	100.03M	2025-12
Amgen	USD 3.96B	464M	2025-12
Bayer	EUR -543M	556M	2025-09
Biogen	USD 659.6M	192.2M	2025-09
BioMarin Pharmaceutical	USD 198.39M	230.08M	2025-12
Bristol-Myers Squibb	USD 4.2B	562M	2025-12
Eli Lilly	USD 8.99B	599.9M	2025-12
Esperion Therapeutics	USD -16.03M	18.6M	2024-09
Gilead Sciences	USD 2.96B	551M	2025-12
Incyte	USD 383.88M	47.43M	2025-12
Merck	USD 6.24B	318M	2025-12
Moderna	USD -857M	597M	2025-12
Neurocrine Biosciences	USD 227.9M	11.4M	2025-12
Novartis	USD 4.5B	363M	2025-09
Pfizer	USD 4.65B	3.99B	2025-12
PTC Therapeutics	USD -81.62M	85.11M	2025-12
Puma Biotechnology	USD 22.08M	24.26M	2024-09
Regeneron Pharmaceuticals	USD 898.6M	211.3M	2025-12
Sangamo BioSciences	USD -33.51M	12.77M	2024-06
Sanofi	EUR 1.7B	2.17B	2025-12
Sanofi	EUR 1.5B	2.29B	2025-12
Sarepta Therapeutics	USD -410.08M	347.2M	2025-12
Teva Pharmaceutical Industries	USD 487M	581M	2025-12
Ultragenyx Pharmaceutical	USD -114M	56.89M	2025-12
United Therapeutics	USD -14.6M	403.9M	2025-12
Vertex Pharmaceuticals	USD 1.26B	24.5M	2025-12

Biogen Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.